Depletion of myeloid-derived suppressor cells sensitizes murine multiple myeloma to PD-1 checkpoint inhibitors

Depletion of myeloid-derived suppressor cells sensitizes murine multiple myeloma to PD-1 checkpoint inhibitors

Background Cancer immunotherapy using immune checkpoint blockade (ICB) has revolutionized cancer treatment. However, patients with multiple myeloma (MM) rarely respond to ICB. Accumulating evidence indicates that the complicated tumor microenvironment (TME) significantly impacts the efficacy of ICB...

Full description

Saved in:

Bibliographic Details
Main Authors:	Qiang Wang, Qing Yi, Wei Xiong, Rui Duan, Jianfei Qian, Liuling Xiao, Miao Xian, Pan Su, Chuanchao Zhang, Yabo Li, Ling Zhong, Chengyun Zheng
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-01-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/13/1/e008979.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Bone Marrow Neutrophils of Multiple Myeloma Patients Exhibit Myeloid-Derived Suppressor Cell Activity
by: Julia Petersson, et al.
Published: (2021-01-01)

Myeloid-Derived Suppressor Cells Participate in Preventing Graft Rejection
by: Yan Wang, et al.
Published: (2012-01-01)

Role of T Regulatory Cells and Myeloid-Derived Suppressor Cells in COVID-19
by: Alhasan Alsalman, et al.
Published: (2022-01-01)

Immunosuppressive Role of Myeloid-Derived Suppressor Cells and Therapeutic Targeting in Lung Cancer
by: Jie Ma, et al.
Published: (2018-01-01)

Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy
by: Shuyan He, et al.
Published: (2025-01-01)

Blockade of TIPE2-Mediated Ferroptosis of Myeloid-Derived Suppressor Cells Achieves the Full Potential of Combinatory Ferroptosis and Anti-PD-L1 Cancer Immunotherapy
by: Hafiza Kashaf Tariq, et al.
Published: (2025-01-01)

PD-1 Checkpoint Blockade in Patients for Acute Myeloid Leukemia after HSCT Relapse Resulted in Severe GVHD and sHLH
by: Zhi zhuo Du, et al.
Published: (2022-01-01)

Depth-dependent PD-L1 sampling of head and neck squamous cell carcinoma (HNSCC) – implications for PD-1/PD-L1 checkpoint inhibitor immunotherapy
by: Madhusudan Roy, et al.
Published: (2024-03-01)

The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment
by: Ze-Tao Zhan, et al.
Published: (2022-01-01)

PD-L1 positive platelets mediate resistance to immune checkpoint inhibitors in patients with colorectal cancer
by: Jiacheng Li, et al.
Published: (2025-01-01)

Targeting Myeloid-Derived Suppressor Cells Is a Novel Strategy for Anti-Psoriasis Therapy
by: Chao Chen, et al.
Published: (2020-01-01)

The Effects of Forodesine in Murine and Human Multiple Myeloma Cells
by: Liesbeth Bieghs, et al.
Published: (2010-01-01)

Eosinophilic Asthma Secondary to Adjuvant Anti-PD-1 Immune Checkpoint Inhibitor Treatment in a Melanoma Patient
by: P. Kissoonsingh, et al.
Published: (2022-01-01)

Letter to the editor, “Depth-dependent PD-L1 sampling of head and neck squamous cell carcinoma (HNSCC) – Implications for PD-1/PD-L1 checkpoint inhibitor immunotherapy.”
by: Geetha Shanmugam
Published: (2024-09-01)

The Crosstalk between Myeloid Derived Suppressor Cells and Immune Cells: To Establish Immune Tolerance in Transplantation
by: Chao Zhang, et al.
Published: (2016-01-01)

Combination of triciribine and p38 MAPK inhibitor PD169316 enhances the differentiation effect on myeloid leukemia cells.
by: Yuri Sato-Nagaoka, et al.
Published: (2024-01-01)

Protocol to detect neutral lipids with BODIPY staining in myeloid-derived suppressor cells in mouse mammary tumors
by: Ukjin Kim, et al.
Published: (2025-03-01)

The impact of PD-L1 polymorphisms on the efficacy of immune checkpoint inhibitors depends on the tumor proportion score: a retrospective study
by: Keiichiro Suminaga, et al.
Published: (2025-02-01)

Advanced anaplastic thyroid carcinoma with positive expression of PD-L1 response to immune checkpoint inhibitors: A case report
by: Shanmin Fan, et al.
Published: (2025-01-01)

Novel role of microphthalmia-associated transcription factor in modulating the differentiation and immunosuppressive functions of myeloid-derived suppressor cells
by: Yoon Kyung Jeon, et al.
Published: (2023-01-01)

The effect of conditioned media on the cellular proliferation of pancreatic cancer cells, pancreatic stellate cells, and myeloid-derived suppressor cells
by: Y. Chong, et al.
Published: (2025-01-01)

Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors
by: Mengqi Zhang, et al.
Published: (2022-01-01)

Subacute parkinsonism induced by immune checkpoint inhibitors
by: Lénia Silva, et al.
Published: (2024-12-01)

Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors
by: Francesca De Felice, et al.
Published: (2015-01-01)

Modeling of Chronic Myeloid Leukemia: An Overview of In Vivo Murine and Human Xenograft Models
by: Pallavi Sontakke, et al.
Published: (2016-01-01)

Editorial: Beyond PD-1: novel checkpoint receptors and ligands as targets for immunotherapy
by: Jesse Haramati, et al.
Published: (2025-02-01)

Sorafenib enhanced the function of myeloid-derived suppressor cells in hepatocellular carcinoma by facilitating PPARα-mediated fatty acid oxidation
by: Chunxiao Li, et al.
Published: (2025-01-01)

Myeloid-derived suppressor cells exhibit distinct characteristics in bone marrow and blood of individuals with diffuse large B-cell lymphoma
by: Paris Efstratiou, et al.
Published: (2025-01-01)

Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation
by: Chang Liu, et al.
Published: (2021-01-01)

Resistance mechanisms to immune checkpoint inhibitors: updated insights
by: Besan H. Alsaafeen, et al.
Published: (2025-01-01)

A review of neurological complications of immune-checkpoint inhibitors
by: D. Valančius, et al.
Published: (2021-12-01)

HDAC1-3 inhibition triggers NEDD4-mediated CCR2 downregulation and attenuates immunosuppression in myeloid-derived suppressor cells
by: Zhiqi Xie, et al.
Published: (2025-02-01)

Siglec-E augments adipose tissue inflammation by modulating TRAF3 signaling and monocytic myeloid-derived suppressor cells during obesity
by: Ahmed Rakib, et al.
Published: (2025-02-01)

Exosomal PVRL4 Promotes Lung Adenocarcinoma Progression by Enhancing the Generation of Myeloid‐Derived Suppressor Cell‐Secreted TGF‐β1
by: Yahai Liang, et al.
Published: (2025-01-01)

Prognostic Role of Monocytic Myeloid-Derived Suppressor Cells in Advanced Non-Small-Cell Lung Cancer: Relation to Different Hematologic Indices
by: Asmaa M. Zahran, et al.
Published: (2021-01-01)

Assessing hemorrhagic risks in combination therapy: implications of angiogenesis inhibitors and immune checkpoint inhibitors
by: Yuhui Yang, et al.
Published: (2025-02-01)

Immune-checkpoint-inhibitor therapy directed against PD-L1 is tolerated in the heart without manifestation of cardiac inflammation in a preclinical reversible melanoma mouse model
by: Caroline Schoenherr, et al.
Published: (2025-01-01)

A Rare Presentation of Checkpoint Inhibitor Induced Distal RTA
by: Andrew V. Doodnauth, et al.
Published: (2021-01-01)

Multiple stellate keratitis during immune checkpoint inhibitor therapy
by: Isana Nakajima, et al.
Published: (2025-03-01)

Unleashing immunity against oral cancer with immune checkpoint inhibitors
by: Ajay Guru
Published: (2024-06-01)